DOXIMITY INC-CLASS A (DOCS) Fundamental Analysis & Valuation

NYSE:DOCS • US26622P1075

25.3 USD
-0.77 (-2.95%)
Last: Mar 6, 2026, 01:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DOCS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

8

Overall DOCS gets a fundamental rating of 8 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

9

1. DOCS Profitability Analysis

1.1 Basic Checks

  • DOCS had positive earnings in the past year.
  • DOCS had a positive operating cash flow in the past year.
  • DOCS had positive earnings in each of the past 5 years.
  • Each year in the past 5 years DOCS had a positive operating cash flow.
DOCS Yearly Net Income VS EBIT VS OCF VS FCFDOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

1.2 Ratios

  • DOCS has a better Return On Assets (20.69%) than 100.00% of its industry peers.
  • Looking at the Return On Equity, with a value of 24.45%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • DOCS has a Return On Invested Capital of 19.48%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 7.01%.
  • The last Return On Invested Capital (19.48%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROIC 19.48%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
DOCS Yearly ROA, ROE, ROICDOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • The Profit Margin of DOCS (37.54%) is better than 100.00% of its industry peers.
  • DOCS's Profit Margin has improved in the last couple of years.
  • DOCS's Operating Margin of 37.44% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
  • DOCS's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 89.75%, DOCS belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
  • DOCS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
DOCS Yearly Profit, Operating, Gross MarginsDOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. DOCS Health Analysis

2.1 Basic Checks

  • DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, DOCS has more shares outstanding
  • The number of shares outstanding for DOCS has been increased compared to 5 years ago.
  • DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DOCS Yearly Shares OutstandingDOCS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DOCS Yearly Total Debt VS Total AssetsDOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • DOCS has an Altman-Z score of 18.39. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 18.39, DOCS belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
  • There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 18.39
ROIC/WACC2.04
WACC9.56%
DOCS Yearly LT Debt VS Equity VS FCFDOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 6.63 indicates that DOCS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.63, DOCS belongs to the top of the industry, outperforming 88.57% of the companies in the same industry.
  • DOCS has a Quick Ratio of 6.63. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DOCS (6.63) is better than 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 6.63
Quick Ratio 6.63
DOCS Yearly Current Assets VS Current LiabilitesDOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. DOCS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.91% over the past year.
  • The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
  • Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 15.92% in the last year.
  • Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%

3.2 Future

  • Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.76% on average per year.
  • The Revenue is expected to grow by 11.82% on average over the next years. This is quite good.
EPS Next Y14.1%
EPS Next 2Y11.43%
EPS Next 3Y11.59%
EPS Next 5Y11.76%
Revenue Next Year13.74%
Revenue Next 2Y11.65%
Revenue Next 3Y11.03%
Revenue Next 5Y11.82%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DOCS Yearly Revenue VS EstimatesDOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
DOCS Yearly EPS VS EstimatesDOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. DOCS Valuation Analysis

4.1 Price/Earnings Ratio

  • DOCS is valuated correctly with a Price/Earnings ratio of 15.33.
  • DOCS's Price/Earnings ratio is rather cheap when compared to the industry. DOCS is cheaper than 85.71% of the companies in the same industry.
  • DOCS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.69.
  • The Price/Forward Earnings ratio is 14.45, which indicates a correct valuation of DOCS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 80.00% of the companies listed in the same industry.
  • DOCS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.79.
Industry RankSector Rank
PE 15.33
Fwd PE 14.45
DOCS Price Earnings VS Forward Price EarningsDOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 68.57% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.21
EV/EBITDA 13.54
DOCS Per share dataDOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

  • DOCS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.09
PEG (5Y)0.19
EPS Next 2Y11.43%
EPS Next 3Y11.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DOCS Dividend Analysis

5.1 Amount

  • No dividends for DOCS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DOCS Fundamentals: All Metrics, Ratios and Statistics

DOXIMITY INC-CLASS A

NYSE:DOCS (3/6/2026, 1:46:04 PM)

25.3

-0.77 (-2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-05
Earnings (Next)05-13
Inst Owners91.38%
Inst Owner Change1.93%
Ins Owners1.96%
Ins Owner Change0.18%
Market Cap4.67B
Revenue(TTM)637.78M
Net Income(TTM)239.40M
Analysts80
Price Target44.25 (74.9%)
Short Float %7.57%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.81%
Min EPS beat(2)1.21%
Max EPS beat(2)16.41%
EPS beat(4)4
Avg EPS beat(4)17.96%
Min EPS beat(4)1.21%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)20.77%
EPS beat(12)12
Avg EPS beat(12)20.67%
EPS beat(16)16
Avg EPS beat(16)21.74%
Revenue beat(2)1
Avg Revenue beat(2)2.2%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)4.82%
Revenue beat(4)3
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-0.43%
Max Revenue beat(4)4.82%
Revenue beat(8)6
Avg Revenue beat(8)3.12%
Revenue beat(12)8
Avg Revenue beat(12)2.38%
Revenue beat(16)11
Avg Revenue beat(16)1.96%
PT rev (1m)-33.6%
PT rev (3m)-37.78%
EPS NQ rev (1m)-10.88%
EPS NQ rev (3m)-10.32%
EPS NY rev (1m)-0.07%
EPS NY rev (3m)3.76%
Revenue NQ rev (1m)-3.99%
Revenue NQ rev (3m)-4.05%
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)1.35%
Valuation
Industry RankSector Rank
PE 15.33
Fwd PE 14.45
P/S 7.33
P/FCF 15.21
P/OCF 14.82
P/B 4.77
P/tB 5.45
EV/EBITDA 13.54
EPS(TTM)1.65
EY6.52%
EPS(NY)1.75
Fwd EY6.92%
FCF(TTM)1.66
FCFY6.57%
OCF(TTM)1.71
OCFY6.75%
SpS3.45
BVpS5.3
TBVpS4.64
PEG (NY)1.09
PEG (5Y)0.19
Graham Number14.03
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROCE 23.71%
ROIC 19.48%
ROICexc 72.13%
ROICexgc 130.98%
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
FCFM 48.17%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 62.82%
Cap/Sales 1.29%
Interest Coverage 250
Cash Conversion 125.24%
Profit Quality 128.33%
Current Ratio 6.63
Quick Ratio 6.63
Altman-Z 18.39
F-Score7
WACC9.56%
ROIC/WACC2.04
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
EPS Next Y14.1%
EPS Next 2Y11.43%
EPS Next 3Y11.59%
EPS Next 5Y11.76%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%
Revenue Next Year13.74%
Revenue Next 2Y11.65%
Revenue Next 3Y11.03%
Revenue Next 5Y11.82%
EBIT growth 1Y6.94%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.93%
EBIT Next 3Y11.51%
EBIT Next 5Y12.86%
FCF growth 1Y90.12%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y89.16%
OCF growth 3Y29.24%
OCF growth 5Y59.83%

DOXIMITY INC-CLASS A / DOCS FAQ

What is the fundamental rating for DOCS stock?

ChartMill assigns a fundamental rating of 8 / 10 to DOCS.


What is the valuation status for DOCS stock?

ChartMill assigns a valuation rating of 6 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.


How profitable is DOXIMITY INC-CLASS A (DOCS) stock?

DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.


What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?

The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 15.33 and the Price/Book (PB) ratio is 4.77.


What is the earnings growth outlook for DOXIMITY INC-CLASS A?

The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.1% in the next year.